Certain Sleep-Disordered Breathing Treatment Systems and Components Thereof: Institution of Investigation Pursuant to 19 U.S.C. 1337, 25475-25476 [2013-10216]

Download as PDF Federal Register / Vol. 78, No. 84 / Wednesday, May 1, 2013 / Notices the information is useful; (2) the accuracy of the agency’s estimate of the burden of the proposed collection of information; (3) ways to enhance the quality, usefulness, and clarity of the information to be collected; and (4) ways to minimize the burden on the respondents, including the use of automated collection techniques or other forms of information technology. We will summarize written responses to this notice and address them in our submission for OMB approval. As a result of your comments, we will make any necessary adjustments to the burden in our submission to OMB. Public Availability of Comments: Before including your address, phone number, email address, or other personal identifying information in your comment, you should be aware that your entire comment—including your personal identifying information—may be made publicly available at any time. While you can ask us in your comment to withhold your personal identifying information from public review, we cannot guarantee that we will be able to do so. Dated: April 25, 2013. Deanna Meyer-Pietruszka, Chief, Office of Policy, Regulations, and Analysis. [FR Doc. 2013–10312 Filed 4–30–13; 8:45 am] BILLING CODE 4310–MR–P INTERNATIONAL TRADE COMMISSION [Investigation No. 337–TA–879] Certain Sleep-Disordered Breathing Treatment Systems and Components Thereof: Institution of Investigation Pursuant to 19 U.S.C. 1337 U.S. International Trade Commission. ACTION: Notice. wreier-aviles on DSK5TPTVN1PROD with NOTICES AGENCY: SUMMARY: Notice is hereby given that a complaint was filed with the U.S. International Trade Commission on March 28, 2013, under section 337 of the Tariff Act of 1930, as amended, 19 U.S.C. 1337, on behalf of ResMed Corporation of San Diego, California; ResMed Incorporated of San Diego, California; and ResMed Limited of Australia. A letter supplementing the Complaint was filed on April 19, 2013. The complaint alleges violations of section 337 based upon the importation into the United States, the sale for importation, and the sale within the United States after importation of certain sleep-disordered breathing treatment systems and components VerDate Mar<15>2010 14:21 Apr 30, 2013 Jkt 229001 thereof by reason of infringement of certain claims of U.S. Patent No. 6,216,691 (‘‘the ’691 patent’’), U.S. Patent No. 6,935,337 (‘‘the ’337 patent’’), U.S. Patent No. 7,159,587 (‘‘the ’587 patent’’), U.S. Patent No. 7,487,772 (‘‘the ’772 patent’’), U.S. Patent No. 7,614,398 (‘‘the ’398 patent’’), U.S. Patent No. 7,743,767 (‘‘the ’767 patent’’), and U.S. Patent No. 7,997,267 (‘‘the ’267 patent’’). The complaint further alleges that an industry in the United States exists as required by subsection (a)(2) of section 337. The complainants request that the Commission institute an investigation and, after the investigation, issue an exclusion order and cease and desist orders. The complaint, except for any confidential information contained therein, is available for inspection during official business hours (8:45 a.m. to 5:15 p.m.) in the Office of the Secretary, U.S. International Trade Commission, 500 E Street SW., Room 112, Washington, DC 20436, telephone (202) 205–2000. Hearing impaired individuals are advised that information on this matter can be obtained by contacting the Commission’s TDD terminal on (202) 205–1810. Persons with mobility impairments who will need special assistance in gaining access to the Commission should contact the Office of the Secretary at (202) 205– 2000. General information concerning the Commission may also be obtained by accessing its internet server at https:// www.usitc.gov. The public record for this investigation may be viewed on the Commission’s electronic docket (EDIS) at https://edis.usitc.gov. FOR FURTHER INFORMATION CONTACT: The Office of Unfair Import Investigations, U.S. International Trade Commission, telephone (202) 205–2560. ADDRESSES: Authority: The authority for institution of this investigation is contained in section 337 of the Tariff Act of 1930, as amended, and in section 210.10 of the Commission’s Rules of Practice and Procedure, 19 CFR 210.10 (2012). Scope of Investigation Having considered the complaint, the U.S. International Trade Commission, on April 24, 2013, ordered that— (1) Pursuant to subsection (b) of section 337 of the Tariff Act of 1930, as amended, an investigation be instituted to determine whether there is a violation of subsection (a)(1)(B) of section 337 in the importation into the United States, the sale for importation, or the sale within the United States after importation of certain sleep-disordered breathing treatment systems and PO 00000 Frm 00062 Fmt 4703 Sfmt 4703 25475 components thereof that infringe one or more of claims 1, 2, 4, 5, 17 and 28 of the ’691 patent; claims 1 and 20 of the ’337 patent; claim 15 of the ’587 patent; claims 1, 5, 6, 11, 12, 18–20, 35 and 36 of the ’772 patent; claims 1–7 of the ’398 patent; claims 59, 60, 63, 72–75 of the ’767 patent; and claims 17, 21–24, 29, 32–37 of the ’267 patent, and whether an industry in the United States exists as required by subsection (a)(2) of section 337; (2) For the purpose of the investigation so instituted, the following are hereby named as parties upon which this notice of investigation shall be served: (a) The complainants are: ResMed Corporation, 9001 Spectrum Center Drive, San Diego, CA 92123. ResMed Incorporated, 9001 Spectrum Center Drive, San Diego, CA 92123. ResMed Limited, 1 Elizabeth Macarthur Drive, Bella Vista NSW 2153, Australia. (b) The respondents are the following entities alleged to be in violation of section 337, and are the parties upon which the complaint is to be served: Apex Medical Corporation, No. 9, Min Sheng Street, Tu-Cheng, New Taipei City, 23679, Taiwan. Apex Medical USA Corporation, 615 North Berry Street, Suite D, Brea, California 92821. Medical Depot Incorporated, d/b/a Drive Medical Design & Manufacturing, 99 Seaview Boulevard, Suite 210, Port Washington, New York 11050. (c) The Office of Unfair Import Investigations, U.S. International Trade Commission, 500 E Street SW., Suite 401, Washington, DC 20436; and (3) For the investigation so instituted, the Chief Administrative Law Judge, U.S. International Trade Commission, shall designate the presiding Administrative Law Judge. Responses to the complaint and the notice of investigation must be submitted by the named respondents in accordance with section 210.13 of the Commission’s Rules of Practice and Procedure, 19 CFR 210.13. Pursuant to 19 CFR 201.16(d)–(e) and 210.13(a), such responses will be considered by the Commission if received not later than 20 days after the date of service by the Commission of the complaint and the notice of investigation. Extensions of time for submitting responses to the complaint and the notice of investigation will not be granted unless good cause therefor is shown. Failure of a respondent to file a timely response to each allegation in the complaint and in this notice may be deemed to constitute a waiver of the E:\FR\FM\01MYN1.SGM 01MYN1 25476 Federal Register / Vol. 78, No. 84 / Wednesday, May 1, 2013 / Notices right to appear and contest the allegations of the complaint and this notice, and to authorize the administrative law judge and the Commission, without further notice to the respondent, to find the facts to be as alleged in the complaint and this notice and to enter an initial determination and a final determination containing such findings, and may result in the issuance of an exclusion order or a cease and desist order or both directed against the respondent. Issued: April 25, 2013. By order of the Commission. Lisa R. Barton, Acting Secretary to the Commission. [FR Doc. 2013–10216 Filed 4–30–13; 8:45 am] BILLING CODE 7020–02–P DEPARTMENT OF JUSTICE Office of Justice Programs [OJP (BJA) Docket No. 1623] Meeting of the Public Safety Officer Medal of Valor Review Board Bureau of Justice Assistance (BJA), Department of Justice. ACTION: Notice of meeting. wreier-aviles on DSK5TPTVN1PROD with NOTICES AGENCY: SUMMARY: This is an announcement of a meeting (via conference call-in) of the Public Safety Officer Medal of Valor Review Board to consider a range of issues of importance to the Board, to include but not limited to: membership/ terms; approval process for meeting minutes; applicant eligibility; 2011– 2012 recommendations; 2012–2013 application submissions and review; outreach efforts; and to vote on the position of Board Chairperson. The meeting/conference call date and time is listed below. DATES: June 5, 2013, 2:00 p.m. to 3:00 p.m. ET. ADDRESSES: This will be a virtual meeting which will take place via video conference and/or conference call. FOR FURTHER INFORMATION CONTACT: Gregory Joy, Policy Advisor, Bureau of Justice Assistance, Office of Justice Programs, 810 7th Street NW., Washington, DC 20531, by telephone at (202) 514–1369, toll free (866) 859– 2687, or by email at gregory.joy@usdoj.gov. The Public Safety Officer Medal of Valor Review Board carries out those advisory functions specified in 42 U.S.C. 15202. Pursuant to 42 U.S.C. 15201, the President of the United States is authorized to award the Public Safety SUPPLEMENTARY INFORMATION: VerDate Mar<15>2010 14:21 Apr 30, 2013 Jkt 229001 Officer Medal of Valor, the highest national award for valor by a public safety officer. The purpose of this meeting/ conference call is to consider a range of issues of importance to the Board, to include but not limited to: membership/ terms; approval process for meeting minutes; applicant eligibility; 2011– 2012 recommendations; 2012–2013 application submissions and review; outreach efforts; and to vote on the position of Board Chairperson. This meeting/conference call is open to the public at the offices of the Bureau of Justice Assistance. For security purposes, members of the public who wish to participate must register at least seven (7) days in advance of the meeting/conference call by contacting Mr. Joy. All interested participants will be required to meet at the Bureau of Justice Assistance, Office of Justice Programs; 810 7th Street NW., Washington, DC and will be required to sign in at the front desk. Note: Photo identification will be required for admission. Additional identification documents may be required. Access to the meeting/conference call will not be allowed without prior registration. Anyone requiring special accommodations should contact Mr. Joy at least seven (7) days in advance of the meeting. Please submit any comments or written statements for consideration by the Review Board in writing at least seven (7) days in advance of the meeting date. Dated: April 29, 2013. Helen Krapels, Assistant General Counsel, U.S. Parole Commission. Gregory Joy, Policy Advisor/Designated Federal Officer, Bureau of Justice Assistance. Office of the Secretary [FR Doc. 2013–10185 Filed 4–30–13; 8:45 am] BILLING CODE 4410–18–P Parole Commission Sunshine Act Meeting 12:00 p.m., Tuesday, May 7, 2013. U.S. Parole Commission, 90 K Street NE., 3rd Floor, Washington, DC PLACE: STATUS: Closed. MATTERS TO BE CONSIDERED: Determination on four original jurisdiction cases. CONTACT PERSON FOR MORE INFORMATION: Patricia W. Moore, Staff Assistant to the Chairman, U.S. Parole Commission, 90 K Street NE., 3rd Floor, Washington, DC 20530, (202) 346–7001. PO 00000 Frm 00063 Fmt 4703 Sfmt 4703 BILLING CODE 4410–31–P DEPARTMENT OF JUSTICE Parole Commission Sunshine Act Meeting 10:00 a.m., Tuesday, May 7, 2013. PLACE: U.S. Parole Commission, 90 K Street NE., 3rd Floor, Washington, DC STATUS: Open. MATTERS TO BE CONSIDERED: Approval of February 12, 2013 minutes; reports from the Chairman, the Commissioners, and senior staff; Comments received on revision of the Rules on Conditions of Release. CONTACT PERSON FOR MORE INFORMATION: Patricia W. Moore, Staff Assistant to the Chairman, U.S. Parole Commission, 90 K Street NE., 3rd Floor, Washington, DC 20530, (202) 346–7001. TIME AND DATE: Dated: April 29, 2013. Helen Krapels, Assistant General Counsel, U.S. Parole Commission. [FR Doc. 2013–10409 Filed 4–29–13; 4:15 pm] BILLING CODE 4410–31–P DEPARTMENT OF LABOR Agency Information Collection Activities; Submission for OMB Review; Comment Request; Benzene Standard ACTION: DEPARTMENT OF JUSTICE TIME AND DATE: [FR Doc. 2013–10415 Filed 4–29–13; 4:15 pm] Notice. SUMMARY: On April 30, 2013, the Department of Labor (DOL) will submit the Occupational Safety and Health Administration (OSHA) sponsored information collection request (ICR) titled, ‘‘Benzene Standard,’’ to the Office of Management and Budget (OMB) for review and approval for continued use in accordance with the Paperwork Reduction Act (PRA) of 1995 (44 U.S.C. 3501 et seq.). DATES: Submit comments on or before May 30, 2013. ADDRESSES: A copy of this ICR with applicable supporting documentation; including a description of the likely respondents, proposed frequency of response, and estimated total burden may be obtained free of charge from the E:\FR\FM\01MYN1.SGM 01MYN1

Agencies

INTERNATIONAL TRADE COMMISSION

[Federal Register Volume 78, Number 84 (Wednesday, May 1, 2013)]
[Notices]
[Pages 25475-25476]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-10216]


=======================================================================
-----------------------------------------------------------------------

INTERNATIONAL TRADE COMMISSION

[Investigation No. 337-TA-879]


Certain Sleep-Disordered Breathing Treatment Systems and 
Components Thereof: Institution of Investigation Pursuant to 19 U.S.C. 
1337

AGENCY: U.S. International Trade Commission.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Notice is hereby given that a complaint was filed with the 
U.S. International Trade Commission on March 28, 2013, under section 
337 of the Tariff Act of 1930, as amended, 19 U.S.C. 1337, on behalf of 
ResMed Corporation of San Diego, California; ResMed Incorporated of San 
Diego, California; and ResMed Limited of Australia. A letter 
supplementing the Complaint was filed on April 19, 2013. The complaint 
alleges violations of section 337 based upon the importation into the 
United States, the sale for importation, and the sale within the United 
States after importation of certain sleep-disordered breathing 
treatment systems and components thereof by reason of infringement of 
certain claims of U.S. Patent No. 6,216,691 (``the '691 patent''), U.S. 
Patent No. 6,935,337 (``the '337 patent''), U.S. Patent No. 7,159,587 
(``the '587 patent''), U.S. Patent No. 7,487,772 (``the '772 patent''), 
U.S. Patent No. 7,614,398 (``the '398 patent''), U.S. Patent No. 
7,743,767 (``the '767 patent''), and U.S. Patent No. 7,997,267 (``the 
'267 patent''). The complaint further alleges that an industry in the 
United States exists as required by subsection (a)(2) of section 337.
    The complainants request that the Commission institute an 
investigation and, after the investigation, issue an exclusion order 
and cease and desist orders.

ADDRESSES: The complaint, except for any confidential information 
contained therein, is available for inspection during official business 
hours (8:45 a.m. to 5:15 p.m.) in the Office of the Secretary, U.S. 
International Trade Commission, 500 E Street SW., Room 112, Washington, 
DC 20436, telephone (202) 205-2000. Hearing impaired individuals are 
advised that information on this matter can be obtained by contacting 
the Commission's TDD terminal on (202) 205-1810. Persons with mobility 
impairments who will need special assistance in gaining access to the 
Commission should contact the Office of the Secretary at (202) 205-
2000. General information concerning the Commission may also be 
obtained by accessing its internet server at 
http:[sol][sol]www.usitc.gov. The public record for this investigation 
may be viewed on the Commission's electronic docket (EDIS) at 
http:[sol][sol]edis.usitc.gov.

FOR FURTHER INFORMATION CONTACT: The Office of Unfair Import 
Investigations, U.S. International Trade Commission, telephone (202) 
205-2560.

    Authority: The authority for institution of this investigation 
is contained in section 337 of the Tariff Act of 1930, as amended, 
and in section 210.10 of the Commission's Rules of Practice and 
Procedure, 19 CFR 210.10 (2012).

Scope of Investigation

    Having considered the complaint, the U.S. International Trade 
Commission, on April 24, 2013, ordered that--
    (1) Pursuant to subsection (b) of section 337 of the Tariff Act of 
1930, as amended, an investigation be instituted to determine whether 
there is a violation of subsection (a)(1)(B) of section 337 in the 
importation into the United States, the sale for importation, or the 
sale within the United States after importation of certain sleep-
disordered breathing treatment systems and components thereof that 
infringe one or more of claims 1, 2, 4, 5, 17 and 28 of the '691 
patent; claims 1 and 20 of the '337 patent; claim 15 of the '587 
patent; claims 1, 5, 6, 11, 12, 18-20, 35 and 36 of the '772 patent; 
claims 1-7 of the '398 patent; claims 59, 60, 63, 72-75 of the '767 
patent; and claims 17, 21-24, 29, 32-37 of the '267 patent, and whether 
an industry in the United States exists as required by subsection 
(a)(2) of section 337;
    (2) For the purpose of the investigation so instituted, the 
following are hereby named as parties upon which this notice of 
investigation shall be served:
    (a) The complainants are:
ResMed Corporation, 9001 Spectrum Center Drive, San Diego, CA 92123.
ResMed Incorporated, 9001 Spectrum Center Drive, San Diego, CA 92123.
ResMed Limited, 1 Elizabeth Macarthur Drive, Bella Vista NSW 2153, 
Australia.
    (b) The respondents are the following entities alleged to be in 
violation of section 337, and are the parties upon which the complaint 
is to be served:

Apex Medical Corporation, No. 9, Min Sheng Street, Tu-Cheng, New Taipei 
City, 23679, Taiwan.
Apex Medical USA Corporation, 615 North Berry Street, Suite D, Brea, 
California 92821.
Medical Depot Incorporated, d/b/a Drive Medical Design & Manufacturing, 
99 Seaview Boulevard, Suite 210, Port Washington, New York 11050.

    (c) The Office of Unfair Import Investigations, U.S. International 
Trade Commission, 500 E Street SW., Suite 401, Washington, DC 20436; 
and
    (3) For the investigation so instituted, the Chief Administrative 
Law Judge, U.S. International Trade Commission, shall designate the 
presiding Administrative Law Judge.
    Responses to the complaint and the notice of investigation must be 
submitted by the named respondents in accordance with section 210.13 of 
the Commission's Rules of Practice and Procedure, 19 CFR 210.13. 
Pursuant to 19 CFR 201.16(d)-(e) and 210.13(a), such responses will be 
considered by the Commission if received not later than 20 days after 
the date of service by the Commission of the complaint and the notice 
of investigation. Extensions of time for submitting responses to the 
complaint and the notice of investigation will not be granted unless 
good cause therefor is shown.
    Failure of a respondent to file a timely response to each 
allegation in the complaint and in this notice may be deemed to 
constitute a waiver of the

[[Page 25476]]

right to appear and contest the allegations of the complaint and this 
notice, and to authorize the administrative law judge and the 
Commission, without further notice to the respondent, to find the facts 
to be as alleged in the complaint and this notice and to enter an 
initial determination and a final determination containing such 
findings, and may result in the issuance of an exclusion order or a 
cease and desist order or both directed against the respondent.

    Issued: April 25, 2013.

    By order of the Commission.
Lisa R. Barton,
Acting Secretary to the Commission.
[FR Doc. 2013-10216 Filed 4-30-13; 8:45 am]
BILLING CODE 7020-02-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.